Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Erasca Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ERAS
Nasdaq
8731
https://www.erasca.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Erasca Inc
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
- Apr 24th, 2024 8:05 pm
Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock?
- Apr 23rd, 2024 4:00 pm
Institutional investors may adopt severe steps after Erasca, Inc.'s (NASDAQ:ERAS) latest 11% drop adds to a year losses
- Apr 16th, 2024 12:14 pm
Erasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call Transcript
- Apr 1st, 2024 8:56 pm
Erasca Inc (ERAS) Aligns with EPS Projections, Reveals Robust Balance Sheet and Key Clinical ...
- Mar 29th, 2024 9:31 am
Erasca Announces $45 Million Oversubscribed Private Placement Financing
- Mar 28th, 2024 12:30 am
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
- Mar 27th, 2024 8:01 pm
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
- Feb 14th, 2024 1:00 pm
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Feb 1st, 2024 1:00 pm
Is Erasca (NASDAQ:ERAS) In A Good Position To Invest In Growth?
- Jan 9th, 2024 11:34 am
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 3rd, 2024 1:00 pm
3 Penny Stocks You’ll Regret Not Buying Soon: December Edition
- Dec 20th, 2023 6:34 pm
Erasca Co-Founder Acquires 3.2% More Stock
- Dec 13th, 2023 10:14 am
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
- Dec 11th, 2023 1:00 pm
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
- Nov 28th, 2023 1:00 pm
Erasca Reports Third Quarter 2023 Financial Results and Business Updates
- Nov 9th, 2023 9:01 pm
Erasca to Present at Upcoming Investor Conferences in November
- Nov 8th, 2023 1:00 pm
With 31% ownership, Erasca, Inc. (NASDAQ:ERAS) has piqued the interest of institutional investors
- Nov 8th, 2023 10:50 am
Insiders Are Betting Millions on These 2 Stocks — Here’s Why You Might Want to Follow Their Lead
- Oct 12th, 2023 3:28 pm
Insider Spends US$2.0m Buying More Shares In Erasca
- Oct 12th, 2023 10:02 am
Scroll